目的观察大鼠颈总动脉球囊损伤后血凝素样氧化低密度脂蛋白受体-1(lectin like oxidized low density lipoprotein receptor-1,LOX-1)的表达及西洛他唑对其表达的影响,探索西洛他唑抑制内膜增生的机制。方法24只健康雄性SD大鼠按完全随...目的观察大鼠颈总动脉球囊损伤后血凝素样氧化低密度脂蛋白受体-1(lectin like oxidized low density lipoprotein receptor-1,LOX-1)的表达及西洛他唑对其表达的影响,探索西洛他唑抑制内膜增生的机制。方法24只健康雄性SD大鼠按完全随机分组法分成假手术组、模型组、西洛他唑组(n=8)。观察球囊损伤后内膜增生情况并计算内膜、中膜面积比值,检测血清MDA含量,RT-PCR法和免疫组化法分别检测各组球囊损伤后大鼠颈总动脉血管壁组织中LOX-1mRNA和蛋白的表达。结果西洛他唑组内膜/中膜面积比值(IA/MA)、LOX-1mRNA及蛋白表达水平、血清MDA含量显著低于模型组,差异有统计学意义(P<0.05)。结论西洛他唑可显著抑制内膜增生,抑制LOX-1表达及其介导的氧化应激,这可能是西洛他唑抑制内膜增生的机制之一。展开更多
Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) is a type-Ⅱ membrane protein belonging to the C-type lectin family molecules, which acts as a cell surface endocytosis receptor for atherogenic oxidized...Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) is a type-Ⅱ membrane protein belonging to the C-type lectin family molecules, which acts as a cell surface endocytosis receptor for atherogenic oxidized LDL (Ox-LDL). LOX-1 supports the binding internalization and proteolytic degradation of oxidized LDL, but not of significant amounts of acetylated LDL. LOX-1 is initially synthesized as a 40 kD precursor protein with N-linked high mannose-type carbohydrate, which is further glycosylated and processed into a 48-kD mature form. In vivo, endothelial cells that cover early therosclerotic lesions, intimal macrophages and smooth muscle cells in advanced atherosclerotic plaques express LOX-1. LOX-1 is cleaved at membrane proximal extracellular domain and released from the cell surface. Measurement of soluble LOX-1 in vivo may provide novel diagnostic strategy for the evaluation and prediction of atherosclerosis and vascular diseases.展开更多
文摘目的观察大鼠颈总动脉球囊损伤后血凝素样氧化低密度脂蛋白受体-1(lectin like oxidized low density lipoprotein receptor-1,LOX-1)的表达及西洛他唑对其表达的影响,探索西洛他唑抑制内膜增生的机制。方法24只健康雄性SD大鼠按完全随机分组法分成假手术组、模型组、西洛他唑组(n=8)。观察球囊损伤后内膜增生情况并计算内膜、中膜面积比值,检测血清MDA含量,RT-PCR法和免疫组化法分别检测各组球囊损伤后大鼠颈总动脉血管壁组织中LOX-1mRNA和蛋白的表达。结果西洛他唑组内膜/中膜面积比值(IA/MA)、LOX-1mRNA及蛋白表达水平、血清MDA含量显著低于模型组,差异有统计学意义(P<0.05)。结论西洛他唑可显著抑制内膜增生,抑制LOX-1表达及其介导的氧化应激,这可能是西洛他唑抑制内膜增生的机制之一。
文摘Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) is a type-Ⅱ membrane protein belonging to the C-type lectin family molecules, which acts as a cell surface endocytosis receptor for atherogenic oxidized LDL (Ox-LDL). LOX-1 supports the binding internalization and proteolytic degradation of oxidized LDL, but not of significant amounts of acetylated LDL. LOX-1 is initially synthesized as a 40 kD precursor protein with N-linked high mannose-type carbohydrate, which is further glycosylated and processed into a 48-kD mature form. In vivo, endothelial cells that cover early therosclerotic lesions, intimal macrophages and smooth muscle cells in advanced atherosclerotic plaques express LOX-1. LOX-1 is cleaved at membrane proximal extracellular domain and released from the cell surface. Measurement of soluble LOX-1 in vivo may provide novel diagnostic strategy for the evaluation and prediction of atherosclerosis and vascular diseases.
